Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

BRISBANE, Calif., May 25, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) will outline the company's corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet® (pirfenidone) in Europe, as well as details on ASCEND, a new Phase 3 pirfenidone study, during a meeting with analysts in New York tomorrow, May 26. InterMune will conduct a live webcast of the presentations beginning at 8:30 a.m. EDT.  

Dan Welch, chairman, CEO and president will open the meeting by discussing key elements of the Company's Vision for 2015 and the five Key Success Factors to realize this Vision:

  • The timely and successful launch of Esbriet in Europe
  • The successful completion of ASCEND and the successful launch of Esbriet in the U.S. in 1H 2014
  • The marketing of Esbriet in territories beyond the EU and U.S.
  • The successful implementation of an aggressive Esbriet Life Cycle Management Strategy
  • The successful implementation of a comprehensive internal and external program to establish an attractive and balanced pipeline

"We have a clear vision of where we expect to be in 2015, and an effective strategy to realize that vision," says Mr. Welch. "We believe our 'Vision 2015' is exciting and realistic and will be realized by successfully executing on the five Key Success Factors that will be detailed tomorrow."  

Esbriet in Europe

On February 28, 2011, the European Commission (EC) granted marketing authorization for Esbriet (pirfenidone) in adults for the treatment of mild to moderate IPF, a progressive and fatal lung disease. Esbriet is now authorized for marketing in all 27 EU member states, as well as in Norway and Iceland.

Based on anticipated EU country reimbursement timelines, InterMune currently plans to launch
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s ... David Dreyer to the Board of Directors ... director and will also serve as chair of the ... 30 years of accounting, financial, compliance and operating experience ... Dreyer has served as chief financial officer, chief operating ...
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
(Date:9/19/2014)... , September 19, 2014 ... Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry ... (Tray-style, Manifold, & Rotary) & Geography - Global ... defines and segments the lyophilization market on the ... analyses and projections of the market size of ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... Mindray Medical International Limited (NYSE: MR ... devices worldwide, announced today an agreement to acquire a ... The terms of the agreement were not disclosed as ... Founded in 2003 and based in Suzhou, China, ...
... NEWARK, N.J., July 5, 2011 Regulators are ... punish corporate officers they suspect of wrongdoing—in effect, ... their jobs. It is unclear whether they intend ... dubbed the "death penalty" by some—but at a ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Suzhou Hyssen Electronics 2Mindray Medical to Acquire a Controlling Stake in Suzhou Hyssen Electronics 3Feds Might 'Banish' More Execs for Misconduct, Attorney Says 2Feds Might 'Banish' More Execs for Misconduct, Attorney Says 3
(Date:9/22/2014)... (PRWEB) September 22, 2014 TherapySites ... titled "From Divorce Talk to Solution Talk: Solution Focused ... The 60-minute webinar, presented by special guest speaker Elliott ... 1pm Central Standard Time. , Reserve Your Seat ... Solution Talk: Solution Focused Brief Therapy with the Most ...
(Date:9/22/2014)... The Ruby Report was launched by ... International Conference in Louisville, Kentucky. This release followed the ... a reception attended by 60 people from the local ... had gained while conducting her research, what drove her ... issue, and what she believes companies can do to ...
(Date:9/21/2014)... CA (PRWEB) September 22, 2014 CareSpan ... it has entered into a joint services agreement with ... Dakota, to deploy the CareSpan Virtual Clinic in multiple ... Avera eCARE plan to deploy their joint services in ... and Wyoming where Avera eCARE is licensed. The two ...
(Date:9/21/2014)... September 22, 2014 UNIWIGS, one of the ... extensions and hair pieces, offers a line of human hair ... trend and it also shows people what the latest ... famous star Rihanna, there are 4 different hairstyles to choose ... of ombre wave lace wigs and a hot ombre red ...
(Date:9/21/2014)... September 21, 2014 More than a quarter of ... dryer fires start in one of two ways. The first ... out properly. The second type of dryer fire occurs when ... (Dryers can also catch fire due to malfunctioning electrical systems so ... to take a look!) Here are some ways that you ...
Breaking Medicine News(10 mins):Health News:TherapySites Presents a Webinar, "From Divorce Talk to Solution Talk: Solution Focused Brief Therapy with the Most Trying of Couples Sessions” with Elliott Connie 2Health News:TherapySites Presents a Webinar, "From Divorce Talk to Solution Talk: Solution Focused Brief Therapy with the Most Trying of Couples Sessions” with Elliott Connie 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3
... and more than 300 people in the UK die from ... permanent disabilities. Now researchers will work on a potential vaccine ... medical charity Meningitis UK. , Although vaccines exist to protect ... to protect against all strains, including the most common in ...
... Immediate Moratorium on Bisphenol,A in Baby Bottles, Food and ... Dozens of state,and national environmental health organizations in the ... the use of bisphenol A (BPA) in baby,bottles and ... of a,new study that demonstrates the toxic chemical BPA ...
... intramuscular injection, study says , , THURSDAY, Feb. 7 ... for delivering DNA vaccines than intramuscular injection, a new ... Genetic Vaccines and Therapy , researchers at the ... protein from the human papillomavirus (HPV), which causes cervical ...
... operating results for the fourth quarter and year ended December 31,2007., Fourth ... $6.883 billion. -- Net income totaled $278 million, ... prior year. -- Adjusted EBITDA totaled $1.153 ... in the prior year. -- Provision for doubtful ...
... DURHAM, NC A novel drug designed to lessen muscle ... at the Duke Clinical Research Institute. Results of the study, ... issue of the journal Circulation, reflect the first time the ... known as KAI-9803, blocks the activity of an enzyme called ...
... 7 Anthera Pharmaceuticals,Inc., a privately held biopharmaceutical ... the Phase II trial,of its novel secretory phospholipaseA2 ... disease will be presented as a late breaker,at ... Scientific Session,on Monday, March 31, 2008 in Chicago, ...
Cached Medicine News:Health News:Meningitis vaccine study gets £200,000 boost 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 4Health News:Tattooing Best Way to Deliver DNA Vaccines 2Health News:HCA Reports Fourth Quarter - Year End 2007 Results 2Health News:HCA Reports Fourth Quarter - Year End 2007 Results 3Health News:HCA Reports Fourth Quarter - Year End 2007 Results 4Health News:HCA Reports Fourth Quarter - Year End 2007 Results 5Health News:HCA Reports Fourth Quarter - Year End 2007 Results 6Health News:HCA Reports Fourth Quarter - Year End 2007 Results 7Health News:HCA Reports Fourth Quarter - Year End 2007 Results 8Health News:HCA Reports Fourth Quarter - Year End 2007 Results 9Health News:HCA Reports Fourth Quarter - Year End 2007 Results 10Health News:HCA Reports Fourth Quarter - Year End 2007 Results 11Health News:HCA Reports Fourth Quarter - Year End 2007 Results 12Health News:HCA Reports Fourth Quarter - Year End 2007 Results 13Health News:HCA Reports Fourth Quarter - Year End 2007 Results 14Health News:HCA Reports Fourth Quarter - Year End 2007 Results 15Health News:Novel compound may lessen heart attack damage 2Health News:Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: